Alpha-Synuclein and Neurodegenerative Diseases
Introduction to Alpha-Synuclein
- Alpha-synuclein is a neuronal protein that plays a critical role in neurodegenerative diseases, particularly serving as the primary component of Lewy bodies in Parkinson's disease and related synucleinopathies, with its abnormal aggregation leading to neurodegeneration and cognitive decline 1, 2
Pathological Role in Neurodegenerative Diseases
- Alpha-synuclein is the predominant component of Lewy bodies, which are proteinaceous inclusions found in Parkinson's disease and cortical Lewy body dementia 2
- Parkinson's disease is a synucleinopathy with neuronal deposits of Lewy bodies predominantly composed of alpha-synuclein and ubiquitin 2
- In Parkinson's disease, Lewy body deposition initially involves the medulla oblongata, pontine tegmentum, and olfactory system, with later involvement of the substantia nigra and other deep gray nuclei, and finally deposition in the cortex 2
Classification and Diagnostic Implications
- Lewy body disease (LBD), including Parkinson's disease and dementia with Lewy bodies, is characterized by abnormal accumulation of alpha-synuclein within inclusions called Lewy bodies, as well as alpha-synuclein-immunoreactive neurites and diffuse cytoplasmic immunoreactivity 3, 4
- LBD can be classified into five categories based on the distribution of alpha-synuclein pathology: none, brainstem-predominant, limbic (transitional), neocortical (diffuse), or amygdala-predominant 4, 5
- Immunohistochemical detection of alpha-synuclein is the preferred method for identifying Lewy bodies, providing greater sensitivity than standard hematoxylin and eosin staining 4, 5
- Immunohistochemical detection of alpha-synuclein is essential for the neuropathological assessment and classification of Lewy body diseases 3, 4
Alpha‑Synuclein Pathology and Clinical Implications in Synucleinopathies
Parkinson’s Disease – Anatomical Progression and Clinical Threshold
- In Parkinson’s disease, neuronal Lewy bodies are composed mainly of alpha‑synuclein and ubiquitin and follow a predictable anatomical progression from the medulla oblongata, pontine tegmentum, and olfactory system to the substantia nigra and deep gray nuclei, and finally to the cerebral cortex 6, 7.
- Clinical motor symptoms typically appear after loss of approximately 40–50 % of dopaminergic neurons in the substantia nigra, which occurs about five years after the onset of neuronal degeneration 6.
Multiple System Atrophy – Distinct Cellular Distribution
- Multiple system atrophy (MSA) is a synucleinopathy characterized by abnormal cytoplasmic inclusions of alpha‑synuclein and ubiquitin that are localized to oligodendroglia rather than neurons 6, 7.
- Compared with Parkinson’s disease and dementia with Lewy bodies, MSA shows a distinct cellular distribution pattern of alpha‑synuclein pathology, supporting its classification as a separate synucleinopathy 6, 7.
Mixed Proteinopathies in Dementia
- Up to 50–60 % of dementia cases exhibit mixed neuropathology, with multiple protein aggregates (e.g., alpha‑synuclein, amyloid‑β, tau) contributing to the clinical picture 8.